Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MKC1106-PP
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intranodal
01
Overview
MKC1106-PP is an experimental "prime-boost" cancer immunotherapy developed by MannKind Corporation, consisting of a DNA plasmid (pSEM) for priming and a synthetic peptide mixture for boosting. It is designed to target five tumor-associated antigens: PRAME, PSMA, SSX2, NY-ESO-1, and Melan-A (MART-1). The therapy is typically administered via ultrasound-guided intranodal injection. While the provided name "Keytruda-Mannkind Corporation-solid tumor" suggests a combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda), the specific trial context (NCT00435552) describes a Phase I study of MKC1106-PP as a monotherapy in patients with advanced, refractory solid malignancies. The combination of a DNA/peptide vaccine with a checkpoint inhibitor is a recognized therapeutic strategy to enhance T-cell responses, although this specific pairing was not the subject of the referenced MannKind trial.
- Brand names
- Keytruda
- Other names
- pSEM + peptides
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + MKC1106-PP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MKC1106-PP.